Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

IMA

Live52w low +43.4%

Annual Quarterly

Core line items from IMA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: ImageneBio, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-07-22	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q1 2025 2025-03-31	Annual 2024 2024-12-31
Revenue	$0.00	$800.00K	$800.00K	$800.00K	$3.50M
Operating Income	Not available	$-48.45M	$-39.95M	$-6.00M	$-37.00M
Net Income	Not available	$-45.35M	$-38.44M	$-6.08M	$-36.57M
EPS (Diluted)	$-0.72	$-9.64	$-9.98	$-3.80	$-22.10
Total Assets	Not available	$152.98M	$160.88M	$130.84M	$15.92M
Total Liabilities	Not available	$19.84M	$21.05M	$12.59M	$17.45M
Cash & Equivalents	Not available	$94.53M	$103.16M	$36.76M	$12.12M
Free Cash Flow OCF − CapEx	Not available	Not available	Not available	Not available	Not available
Shares Outstanding	Not available	4.87M	3.81M	48.26M	48.26M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from IMA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +43.4%

Entity: ImageneBio, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-07-22	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q1 2025 2025-03-31	Annual 2024 2024-12-31
Revenue	$0.00	$800.00K	$800.00K	$800.00K	$3.50M
Operating Income	Not available	$-48.45M	$-39.95M	$-6.00M	$-37.00M
Net Income	Not available	$-45.35M	$-38.44M	$-6.08M	$-36.57M
EPS (Diluted)	$-0.72	$-9.64	$-9.98	$-3.80	$-22.10
Total Assets	Not available	$152.98M	$160.88M	$130.84M	$15.92M
Total Liabilities	Not available	$19.84M	$21.05M	$12.59M	$17.45M
Cash & Equivalents	Not available	$94.53M	$103.16M	$36.76M	$12.12M
Free Cash Flow OCF − CapEx	Not available	Not available	Not available	Not available	Not available
Shares Outstanding	Not available	4.87M	3.81M	48.26M	48.26M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.